Lexeo Therapeutics (LXEO) Other financing activities (2022 - 2026)

Lexeo Therapeutics has reported Other financing activities for 5 years, with the latest figure at $9000.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.5 million (changed N/A YoY) and the FY2025 annual result came in at $59000.0, down 87.98% from the prior year.
• Other financing activities slipped to $9000.0 in Q1 2026 per LXEO's latest filing, from $25000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $88.8 million in Q1 2024 and troughed at -$94.5 million in Q4 2024.
• A 5-year average of $67111.1 and a median of $25000.0 in 2025 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2024 and 2025: Other financing activities surged 739508.33% in 2024, then surged 100.03% in 2025.
• Over 5 years, Other financing activities stood at $28000.0 in 2022, then increased by 7.14% to $30000.0 in 2023, then tumbled by 315126.67% to -$94.5 million in 2024, then soared by 100.03% to $25000.0 in 2025, then sank by 64.0% to $9000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $9000.0, $25000.0, and -$94.5 million for Q1 2026, Q4 2025, and Q4 2024 respectively.